Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 76 to 100 of 881

TitleReference numberPublishedLast updated
Avapritinib for treating advanced systemic mastocytosisTA1012
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal)TA730
Avatrombopag for treating primary chronic immune thrombocytopeniaTA853
Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedureTA626
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapyTA788
Avelumab for treating metastatic Merkel cell carcinomaTA517
Avelumab for untreated metastatic Merkel cell carcinomaTA691
Avelumab with axitinib for untreated advanced renal cell carcinomaTA1120
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapiesTA872
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapyTA895
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphomaTA894
Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatmentTA333
Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemiaTA218
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blastsTA399
Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal)TA732
Baricitinib for moderate to severe rheumatoid arthritisTA466
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)TA982
Baricitinib for treating moderate to severe atopic dermatitisTA681
Baricitinib for treating severe alopecia areataTA926
Belimumab for treating active autoantibody-positive systemic lupus erythematosusTA752
Belimumab for treating lupus nephritis (terminated appraisal)TA806
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and overTA949
Belzutifan for treating tumours associated with von Hippel-Lindau diseaseTA1011
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemiaTA694
Bendamustine for the first-line treatment of chronic lymphocytic leukaemiaTA216

Results per page

  1. 10
  2. 25
  3. 50
  4. All